923595-49-7

Basic information

• Product Name: 6-CHLORO-3-IODOIMIDAZO[1,2-B]PYRIDAZINE
• Synonyms: 6-CHLORO-3-IODOIMIDAZO[1,2-B]PYRIDAZINE;6-Chloro-3-iodoimidazo[1,2-a]pyridazine
• CAS NO: 923595-49-7
• Molecular Formula: C6H3ClIN3
• Molecular Weight: 279.47
• EINECS: 200-001-2
• Mol File: 923595-49-7.mol
• Article Data: 11

Chemical Properties

• Appearance: /
• Density: 2.34
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 1.03±0.30(Predicted)
• CAS DataBase Reference: 6-CHLORO-3-IODOIMIDAZO[1,2-B]PYRIDAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-CHLORO-3-IODOIMIDAZO[1,2-B]PYRIDAZINE(923595-49-7)
• EPA Substance Registry System: 6-CHLORO-3-IODOIMIDAZO[1,2-B]PYRIDAZINE(923595-49-7)

Safety Data

• Hazard Codes: Xi
• Statements: 43
• Safety Statements: 36/37
• Hazardous Substances Data: 923595-49-7(Hazardous Substances Data)

Usage

General Description

6-Chloro-3-iodoimidazo[1,2-b]pyridazine is a chemical compound with the molecular formula C6H3ClIN3. It is a heterocyclic compound containing both chlorine and iodine atoms, and it belongs to the imidazopyridazine class of chemicals. 6-Chloro-3-iodoimidazo[1,2-b]pyridazine is known for its potential use in pharmaceutical research and drug development, particularly in the field of medicinal chemistry. It may have applications in the synthesis of biologically active molecules or as a starting material for the preparation of pharmaceutical products. Its chemical structure and properties make it a potentially valuable building block for the development of new drugs. Further studies and research may reveal its potential uses and benefits in various fields.

Upstream product

• 6775-78-6 6-chloroimidazo[1,2-b]pyridazine 

Downstream Products

• 1426845-13-7 2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)-5-(3-(4-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazin-6-yl)benzofuran-3-carboxamide 
• 1025065-94-4 6-chloro-3-(4-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine 

Relevant articles and documents

INHIBITORS OF LIN28 AND METHODS OF USE THEREOF

The present disclosure relates to compounds of formula (I) and compositions comprising the same. The disclosure further relates to methods of treating cancers.

Discovery of Potent, Selective, and Brain-Penetrant 1 H-Pyrazol-5-yl-1 H-pyrrolo[2,3- b]pyridines as Anaplastic Lymphoma Kinase (ALK) Inhibitors

Anaplastic lymphoma kinase (ALK), a member of the receptor tyrosine kinase family, is predominantly expressed in the brain and implicated in neuronal development and cognition. However, the detailed function of ALK in the central nervous system (CNS) is s

Antiplasmodial imidazopyridazines: structure-activity relationship studies lead to the identification of analogues with improved solubility and hERG profiles

3,6-Diarylated imidazopyridazines have recently been shown to possess good in vitro antiplasmodial and in vivo antimalarial activity. However, frontrunner compounds have been associated with poor solubility and a hERG (human ether-a-go-go-related gene) inhibition liability raising concerns for potential cardiotoxicity risks. Herein, we report the synthesis and structure-activity relationship studies of new imidazopyridazines aimed at improving aqueous solubility and countering hERG inhibition while maintaining antiplasmodial potency. While we identified new analogues with potent antiplasmodial activity (IC50 = 0.031 μM against the NF54 drug-sensitive strain, and IC50 = 0.0246 μM against the K1 multidrug resistant strain), hERG inhibition remained an issue. Excitingly, on the other hand, new analogues with a substantially improved hERG inhibition profile (IC50 = 7.83-32.3 μM) with sub-micromolar antiplasmodial activity (NF54, IC50 = 0.151-0.922 μM) were identified. Similarly, the introduced molecular features also resulted in analogues with moderate to high solubility (60-200 μM) while also displaying sub-micromolar antiplasmodial potency (NF54, IC50 = 0.136-0.99 μM).